Class Action Lawsuit Targets Kyndryl's Free Cash Flow Reporting, Heightening Turnaround Execution Risks

What happened

National shareholder rights firm Hagens Berman has expanded a securities class action against Kyndryl, introducing new allegations regarding the company's free cash flow reporting, which directly challenges a key metric in its turnaround narrative. Kyndryl, amid a complex transition from losses to profitability, has guided for FY26 free cash flow of approximately $550M, up from $446M in FY25, but the DeepValue report notes significant volatility, with H1 FY26 operating cash flow at just $22M. Management's credibility is already under strain from repeated revenue misses and delays in achieving clean growth, despite margin improvements driven by cost actions and contract remediation. The lawsuit alleges potential misreporting in free cash flow, amplifying existing concerns about transparency and the sustainability of cash generation metrics critical to valuation. This legal overhang adds reputational and financial risk to an equity story already discounted for execution uncertainty.

Implication

Investors must anticipate increased volatility as the class action casts doubt on the accuracy of Kyndryl's free cash flow figures, a cornerstone of its valuation and turnaround thesis. Should allegations prove substantial, they could trigger financial restatements, regulatory penalties, and a deeper erosion of management credibility, directly undermining the investment case. The stock, already down ~30% over twelve months, may face additional selling pressure from risk-averse investors and potential institutional outflows, exacerbating downside risks. From a valuation perspective, the current discounted multiples (e.g., ~5.5x EV/EBITDA) may not fully account for the heightened risk of cash flow misreporting and associated legal costs. Long-term, this could impair Kyndryl's ability to secure capital and execute its strategic initiatives, diverting management focus and resources toward legal defenses rather than operational improvements.

Thesis delta

The class action lawsuit directly questions the reliability of Kyndryl's free cash flow reporting, a critical component of the turnaround thesis that hinges on margin expansion and cash generation targets. This amplifies pre-existing risks identified in the DeepValue report, such as cash flow volatility and management credibility issues, potentially shifting the rating from Potential Buy to a more cautious Wait or Sell if evidence of misconduct emerges. Investors should closely monitor the lawsuit's developments and any revisions to FY26 cash flow guidance, as these will be pivotal in reassessing the investment case amid heightened uncertainty.